sglt2 inhibitors and glp-1 receptor agonists together GLP1 vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Cardiovascular benefits of SGLT2 inhibitors

Last updated: July 22, 2026 Reviewed monthly as formularies and coverage policies change Disclaimer The information on this page is for educational and informational purposes only and is not intended as medical advice

van der Harst, N

This small, open-label safety study performed for the regulatory authorities in Japan reported nausea as the most commonly reported adverse event, with no new safety signals observed [13]

Every now and again, we fall ill either through stress or by catching an infection that is going round

Overall facial contours may look slightly more lifted

While Health Canada didn't specifically say which brand-name medications are included in its review, the following will likely be under consideration, along with Ozempic: Novo Nordisk's Wegovy, which is approved in Canada for people with obesity but is not yet available to patients